World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
116
Citations
79825
World Ranking
4260
National Ranking
232

Overview

Michael Untch is affiliated with Helios Klinikum Berlin-Buch in Germany and has an extensive publication record in the field of medicine, focusing primarily on oncology and breast cancer research. Their work spans clinical trials, molecular characterization studies, and treatment evaluations related to breast cancer, particularly targeting early-stage and advanced therapies.

Their recent papers include:

  • Pembrolizumab for Early Triple-Negative Breast Cancer (2020) published in New England Journal of Medicine
  • Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials (2021) published in The Lancet Oncology
  • Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial (2021) published in Journal of Clinical Oncology
  • Ribociclib plus Endocrine Therapy in Early Breast Cancer (2024) published in New England Journal of Medicine
  • Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (2024) published in New England Journal of Medicine

Frequent coauthors working alongside Michael Untch include:

  • Peter A. Fasching
  • Andreas Schneeweiß
  • Sibylle Loibl
  • Volkmar Müller
  • Elmar Stickeler

The scientist's work is published across several notable journals with multiple contributions to:

  • Geburtshilfe und Frauenheilkunde
  • Cancer Research
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie
  • Annals of Oncology
  • Journal of Clinical Oncology

Michael Untch's main fields of study are:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader fields, their subfields include:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine
  • Genetics

Their research covers key topics such as:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Breast Lesions and Carcinomas
  • Cancer Genomics and Diagnostics

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

    Thorsten Kuehn;Ingo Bauerfeind;Tanja Fehm;Barbara Fleige

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn

  • Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

    Gottfried E. Konecny;Mark D. Pegram;Natarajan Venkatesan;Richard Finn

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

    Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl

  • Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

    Gottfried Konecny;Giovanni Pauletti;Murk Pegram;Michael Untch

  • Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

    Luca Gianni;Urania Dafni;Richard D Gelber;Evandro Azambuja

  • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Sibylle Loibl;Joyce O'Shaughnessy;Michael Untch;William M Sikov

Frequent Co-Authors

Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Jens Huober
Jens Huober Kantonsspital St. Gallen
Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Volkmar Müller
Volkmar Müller Universität Hamburg
Christoph Thomssen
Christoph Thomssen University of Göttingen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens doors to a diverse range of healthcare professions, many of which can be pursued through flexible online programs. For those interested in healthcare leadership, consider the most affordable online mha programs. These degrees focus on the management and administration of hospitals and health systems, equipping graduates for leadership roles.

Aspiring advanced practice nurses may benefit from the cheapest dnp programs online. These Doctor of Nursing Practice (DNP) programs emphasize high-level clinical skills and evidence-based practice, all while offering a flexible schedule for working professionals.

For those drawn to pharmacy, there are pharmd online programs that make it possible to earn a Doctorate in Pharmacy from home. These programs blend online coursework with on-site clinical rotations, preparing students for licensure and practice.

Finally, the healthcare industry increasingly relies on data and technology. A career in health informatics can start with one of the health informatics degrees available online, which prepare graduates for roles at the intersection of healthcare and information systems.

Best Scientists Citing Michael Untch

Trending Scientists

Recently Published Articles